Details of the Drug Reposition

Tocilizumab DM7J6OR

Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody

Monoclonal antibody

General Information of This Drug (ID: DM7J6OR)

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Giant cell arteritis	DISSP87T	4A44.2	Approved	[1]
------------------------------------------------------------------------------------

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Phase 3	[2]
Juvenile idiopathic arthritis	DISQZGBV	FA24	Phase 3	[3]
------------------------------------------------------------------------------------

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Rheumatoid arthritis	DISTSB4J	FA20	Discontinued in Phase 2	[4]
------------------------------------------------------------------------------------

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Castleman's disease	DISVC11M	4B2Y	Investigative	[5]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT04320615) A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881).
4	Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
5	Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020;98(3):131-137.